» Articles » PMID: 34248606

Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders

Overview
Specialty Geriatrics
Date 2021 Jul 12
PMID 34248606
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Lewy Body Disorders (LBDs) lie within the spectrum of age-related neurodegenerative diseases now frequently categorized as the synucleinopathies. LBDs are considered to be among the second most common form of neurodegenerative dementias after Alzheimer's disease. They are progressive conditions with variable clinical symptoms embodied within specific cognitive and behavioral disorders. There are currently no effective treatments for LBDs. LBDs are histopathologically characterized by the presence of abnormal neuronal inclusions commonly known as Lewy Bodies (LBs) and extracellular Lewy Neurites (LNs). The inclusions predominantly comprise aggregates of alpha-synuclein (aSyn). It has been proposed that post-translational modifications (PTMs) such as aSyn phosphorylation, ubiquitination SUMOylation, Nitration, o-GlcNacylation, and Truncation play important roles in the formation of toxic forms of the protein, which consequently facilitates the formation of these inclusions. This review focuses on the role of different PTMs in aSyn in the pathogenesis of LBDs. We highlight how these PTMs interact with aSyn to promote misfolding and aggregation and interplay with cell membranes leading to the potential functional and pathogenic consequences detected so far, and their involvement in the development of LBDs.

Citing Articles

Inspecting the Triazole Scaffold as Powerful Antifibril Agents against 2N4R Tau and α-Synuclein Aggregates.

Elbatrawy A, Ademoye T, Alnakhala H, Tripathi A, Zhu X, Plascencia-Villa G ACS Omega. 2025; 10(7):6721-6734.

PMID: 40028124 PMC: 11866179. DOI: 10.1021/acsomega.4c08385.


Lipid Packing Defects are Necessary and Sufficient for Membrane Binding of α-Synuclein.

Johnson D, Kou O, White J, Ramirez S, Margaritakis A, Chung P bioRxiv. 2025; .

PMID: 39829920 PMC: 11741239. DOI: 10.1101/2024.11.14.623669.


Ultrasensitive Protein Aggregate Quantification Assays for Neurodegenerative Diseases on the Simoa Platform.

Boken D, Xia Z, Lam J, Fertan E, Wu Y, English E Anal Chem. 2024; 97(1):290-299.

PMID: 39718440 PMC: 11740166. DOI: 10.1021/acs.analchem.4c04188.


Structures of Oligomeric States of Tau Protein, Amyloid-β, α-Synuclein and Prion Protein Implicated in Alzheimer's Disease, Parkinson's Disease and Prionopathies.

Cehlar O, Njemoga S, Horvath M, Cizmazia E, Bednarikova Z, Barrera E Int J Mol Sci. 2024; 25(23).

PMID: 39684761 PMC: 11641156. DOI: 10.3390/ijms252313049.


Alpha-synuclein in mitochondrial dysfunction: opportunities or obstacles.

Gunawardena S Neural Regen Res. 2024; 20(1):197-198.

PMID: 39657088 PMC: 11246122. DOI: 10.4103/NRR.NRR-D-23-01966.


References
1.
Vasquez V, Mitra J, Hegde P, Pandey A, Sengupta S, Mitra S . Chromatin-Bound Oxidized α-Synuclein Causes Strand Breaks in Neuronal Genomes in in vitro Models of Parkinson's Disease. J Alzheimers Dis. 2017; 60(s1):S133-S150. PMC: 6172953. DOI: 10.3233/JAD-170342. View

2.
McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

3.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

4.
Choi M, Kim M, Kim D, Yu R, Jang Y, Oh W . Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide. PLoS One. 2018; 13(4):e0195339. PMC: 5880409. DOI: 10.1371/journal.pone.0195339. View

5.
Kahle P . alpha-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2007; 115(1):87-95. DOI: 10.1007/s00401-007-0302-x. View